MIAMI, July 1, 2025 /PRNewswire/ -- Lavior Pharma Inc., a woman-owned pharmaceutical company developing innovative therapies for chronic and acute conditions, today announced the appointment of Dr. Imaze Marian Davis, DPM, MBA, DABPM, CWSP, DABMSP, FACPM, FFPM RCPS (Glasg), as Chief Medical Officer, effective immediately. This strategic hire underscores the company's commitment to clinical excellence and women's leadership in the pharmaceutical industry.
"Dr. Davis brings an extraordinary blend of clinical expertise, surgical acumen, and strategic vision," said Anabelle Savion, Co-Founder and COO. "Her credentials in wound care and diabetic foot ulcer management—alongside board certifications in podiatric medicine, surgery, and wound healing—will be pivotal as we advance our pipeline. Appointing a distinguished woman physician as CMO reflects our values of diversity, equity, and excellence."
"Her track record in reducing amputations through innovative protocols and her passion for mentoring future physicians align perfectly with our mission," added Gilad Savion, CEO. "I look forward to Dr. Davis's guidance as we accelerate clinical programs and bring new treatments to market."
Dr. Davis joins Lavior after nearly 20 years leading wound-care and diabetic foot initiatives—and almost two years on Lavior's Advisory Board, where she guided clinical-trial design and protocol development. Inspired by our platform's superior healing in chronic wounds, she embraced the CMO role.
Born in Benin City, Nigeria, Dr. Davis earned her Doctorate in Podiatric Medicine and MBA from Barry University in 2006. After completing her surgical residency at Westchester General Hospital, she became Director of the Wound Healing Center at North Shore Medical Center, turning it into a regional referral hub that significantly reduced amputation rates.
A diplomate of both the American Board of Multiple Specialties in Podiatry and the American Board of Podiatric Medicine, she holds certifications in primary care podiatric medicine, podiatric surgery, minimally invasive surgery, and is a Certified Wound Specialist Physician. She has also participated in advanced wound-care surgical training programs with North Shore Medical Center, Jackson Health System, Hialeah Hospital, and Aventura Hospital.
Elected to the ABPM Board in 2023, Dr. Davis champions the "Podiatry Forward" initiative with her colleagues to improve diabetic patient outcomes.
"I am honored to join Lavior Pharma at such an exciting time," said Dr. Davis. "Their commitment to next-generation therapies for diabetic foot ulcers and other challenging wounds aligns with my life's work. I look forward to collaborating across R&D, regulatory affairs, and clinical operations to bring life-changing treatments to patients."
About Lavior Pharma Inc.
Lavior Pharma Inc. is a woman-owned pharmaceutical company focused on first-in-class therapies for complex, underserved conditions—especially diabetic foot ulcers and chronic wounds. Our mission is to leverage cutting-edge science and inclusive leadership to transform patient care. For more information, visit www.lavior.com or follow us on social media (@LaviorPharma).
Media Contact:
Anabelle Savion
Co-Founder and COO, Lavior Pharma Inc.
305-627-3680 • 397332@email4pr.com
SOURCE Lavior
